Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RCEL 
Avita Medical Ltd (RCEL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/12/2025: RCEL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.98
1 Year Target Price $8.98
| 3 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.18% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 123.21M USD | Price to earnings Ratio - | 1Y Target Price 8.98 |
Price to earnings Ratio - | 1Y Target Price 8.98 | ||
Volume (30-day avg) 4 | Beta 1.58 | 52 Weeks Range 3.60 - 14.16 | Updated Date 09/14/2025 |
52 Weeks Range 3.60 - 14.16 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.97 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -68.87% | Operating Margin (TTM) -60.53% |
Management Effectiveness
Return on Assets (TTM) -40.03% | Return on Equity (TTM) -935.73% |
Valuation
Trailing PE - | Forward PE 4.82 | Enterprise Value 152104339 | Price to Sales(TTM) 1.65 |
Enterprise Value 152104339 | Price to Sales(TTM) 1.65 | ||
Enterprise Value to Revenue 2.03 | Enterprise Value to EBITDA -6.17 | Shares Outstanding 27018900 | Shares Floating 26055411 |
Shares Outstanding 27018900 | Shares Floating 26055411 | ||
Percent Insiders 0.91 | Percent Institutions 29.13 |
Upturn AI SWOT
Avita Medical Ltd
Company Overview
History and Background
Avita Medical Ltd is a regenerative medicine company focused on developing and commercializing innovative products for the treatment of burns, wounds, and skin defects. Originally founded in Australia, the company has expanded its operations globally, including a significant presence in the US. Key milestones include FDA approval of RECELL System for burn treatment.
Core Business Areas
- Burn Care: Focuses on providing solutions for burn treatment, primarily through the RECELL System.
- Wound Care: Extends RECELL System application to chronic wounds and other skin defects.
- Dermatology: Exploring the use of RECELL technology in dermatological applications.
Leadership and Structure
Avita Medical Ltd is led by a management team with experience in regenerative medicine and commercialization. The organizational structure includes departments for research and development, manufacturing, sales and marketing, and clinical operations.
Top Products and Market Share
Key Offerings
- RECELL System: The RECELL System is Avita Medical's flagship product. It enables clinicians to prepare Spray-On Skin Cells using a small sample of the patientu2019s own skin, allowing for faster healing and reduced donor site requirements. Competitors include conventional skin grafting and synthetic skin substitutes. The market share for RECELL within its targeted applications is growing but remains a smaller portion of the overall wound care market.
Market Dynamics
Industry Overview
The regenerative medicine industry is rapidly evolving, with increasing demand for advanced wound care solutions. Key trends include the development of cell-based therapies and personalized medicine approaches.
Positioning
Avita Medical is positioned as a leader in cell-based skin regeneration, offering a unique solution with the RECELL System. Its competitive advantages include clinical evidence supporting the efficacy and safety of its technology.
Total Addressable Market (TAM)
The global wound care market is estimated to be worth billions of dollars annually. Avita Medical is targeting specific segments within this market, including burn care and chronic wounds, with significant growth potential. The TAM for RECELL is estimated to be around $500 million, and Avita is positioning itself to capture a significant portion of that market.
Upturn SWOT Analysis
Strengths
- Proprietary RECELL technology
- Clinical evidence of efficacy
- FDA approved product
- Strong intellectual property protection
Weaknesses
- Limited market penetration
- Reliance on a single product
- High cost of goods sold
- Cash burn
Opportunities
- Expanding indications for RECELL System
- Geographic expansion into new markets
- Strategic partnerships and collaborations
- New reimbursement pathways
Threats
- Competition from established wound care companies
- Regulatory hurdles and delays
- Reimbursement challenges
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- MDT
- BSX
- STMI
Competitive Landscape
Avita Medical's advantages include its proprietary technology and clinical evidence. Its disadvantages include its smaller size and limited market reach compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Avita Medical has experienced rapid revenue growth in recent years, driven by increased adoption of the RECELL System.
Future Projections: Analysts project continued revenue growth for Avita Medical, driven by expanding indications and geographic reach.
Recent Initiatives: Recent initiatives include expanding the RECELL System's applications, increasing manufacturing capacity, and pursuing new reimbursement agreements.
Summary
Avita Medical is a regenerative medicine company with a promising technology, the RECELL System, for burn and wound care. It is experiencing rapid revenue growth but needs to achieve profitability. Expanding into new markets and indications represents significant growth opportunities. Competition from larger wound care companies and reimbursement challenges are key risks to watch.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, analyst reports, industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avita Medical Ltd
Exchange NASDAQ | Headquaters Valencia, CA, United States | ||
IPO Launch date 2019-10-01 | CEO, President & Executive Director Mr. James M. Corbett | ||
Sector Healthcare | Industry Medical Devices | Full time employees 260 | Website https://avitamedical.com |
Full time employees 260 | Website https://avitamedical.com | ||
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company markets, sells, and distributes PermeaDerm, a biosynthetic wound matrix; and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.